Study Comparing Bioavailability of Oral Formulations of Vabicaserin

A Randomized, Open-Label, Single-Dose, 4-Period Crossover, Comparative Bioavailability Study of 3 Sustained- Release Formulations and an Immediate- Release Formulation of Vabicaserin (SCA-136) in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00541996

Enrollment

Unknown

Registered

2007-10-10

Start date

2007-08-31

Completion date

2007-10-31

Last updated

2007-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.

Interventions

DRUGvabicaserin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy men aged 18-50 years.

Exclusion criteria

* Any significant disease state. * History of drug or alcohol abuse within 1 year. * Abnormal liver function tests.

Design outcomes

Primary

Measure	Time frame
Assess the bioavailability of four oral formulations of vabicaserin.	—

Secondary

Measure	Time frame
Obtain additional safety and tolerability data for vabicaserin in healthy male subjects.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026